Archive for the ‘cryonics’ category

Aug 3, 2023

Storing dead people at —196°C

Posted by in categories: cryonics, law, life extension

In Switzerland, there’s a new cryonics company: and they invited me to have a look around. I had questions: legal, practical, and ethical, and I want to be clear: this is not an endorsement. I just wasn’t going to turn down that invitation. ■ Tomorrow Bio:

Camera: Martin Bäbler.

Continue reading “Storing dead people at —196°C” »

Jul 26, 2023

New Breakthroughs In Cryopreservation Poised To Transform Organ Transplantation

Posted by in categories: biotech/medical, cryonics, life extension

In 2023, several breakthroughs have shaken the academic community. Freezing entire organs to sub-zero temperatures for future transplantation is now a reality.

Jul 14, 2023

What ever happened to the first cryogenically frozen humans?

Posted by in categories: biotech/medical, cryonics, life extension

For decades, people have arranged to freeze their bodies after death, dreaming of resurrection by advanced future medicine.

Jun 17, 2023

Cryonics, or wake me up when I can live forever

Posted by in categories: cryonics, life extension

Some people choose cryopreservation after death, hoping future technology will revive them for eternal life.

Apr 27, 2023

Recent clinical trials with stem cells to slow or reverse normal aging processes

Posted by in categories: biotech/medical, cryonics, finance, life extension, nuclear energy

Stem cells (SCs) are undifferentiated cells which can proliferate indefinitely or differentiate into progenitor cells and end-phase differentiated cells (becoming pluripotent) (Mayo, 2021; Slack, 2022). Human embryonic SCs (hE-SCs) are found in the inner cell mass of the blastocyst; h E-SC research raises ethical concerns (Lo and Parham, 2009), and h E-SC transplantation in vivo can lead to the formation of large tumors called teratomas (Blum and Benvenisty, 2008).

Small numbers of adult SCs are found in some organ “niches”, including the bone marrow, where hematopoietic progenitor cells (HPC) replenish blood and immune cells. In 1958, Mathe et al. (1959) successfully performed the first adult SC therapy on five workers who had received high-dose accidental irradiation at the Vinca Nuclear Institute in Yugoslavia. After transfusions and grafts of homologous adult bone marrow, all workers survived (Mathe et al., 1959).

For years, the human umbilical cord was a waste material and, unlike h E-SCs, its use does not raise ethical concerns. In 1988, Gluckman et al. (1989) successfully performed the first human cord blood transplant in a child with Fanconi’s anemia. Since then, numerous public and private cord blood banks have been established worldwide for the cryopreservation of cord blood in view of its transplantation (Gluckman, 2011).

Apr 2, 2023

A Disease Reversal Therapy That No Body Try Before

Posted by in categories: biotech/medical, cryonics, genetics, life extension

Previously Fahy has reported as much as a 15 year epigenetic clock reset. Again though, this won’t get you beyond your maximum natural limit, but younger and healthier now leads to the next bridge.

Dr Greg Fahy talks about the thymus magic. What are the out of expectation benefits of reprogramming our thymus(Not TRIIM or TRIIM-X) in this short clip.

Continue reading “A Disease Reversal Therapy That No Body Try Before” »

Apr 1, 2023

The CryoPrize (The Organ Cryopreservation Prize)

Posted by in categories: biotech/medical, cryonics, life extension

PLEASE CLICK ON LINK TO DONATE: 3 Minute video detailing our efforts to make organ transplants safer, less costly and more available to those in need by offering a prize, beginning at $50,000, to the first person or group to successfully freeze, and restore to full function, one of several mammalian organs.

Mar 30, 2023

Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats

Posted by in categories: biotech/medical, cryonics, life extension, neuroscience

The hNSCs used in the study have been produced and characterised in the Cell Factory and Biobank of Santa Maria Hospital (Terni, Italy), authorised by the Italian Medicine Agency (AIFA) for the production of hNSCs to be used for clinical trials (aM 54/2018). The methodology applied to isolate, expand, characterise and cryopreserve the lines is based on the Neurosphere Assay26,41,54, and has been used for the production of the cells utilised in phase I trials for Amyotrophic Lateral Sclerosis patients (NCT0164006723) and for Secondary Progressive Multiple Sclerosis patients (NCT03282760, ongoing).

The entire production process, starting from tissue procurement to cryopreservation is compliant to cGMP guidelines and approved by AIFA. The hNSCs are obtained from foetal brain tissue derived from fetuses that underwent miscarriage or natural in utero death upon receiving the signed informed consent from the mother. Forty-eight hours prior to implantation, hNSCs were plated in the growth medium at a concentration of 10,000 cells/cm2. On the day of surgery, hNSCs were collected by centrifugation, viable cells were counted by Trypan blue exclusion criteria, and the correct number of cells were re-suspended in HBSS for the transplant.

SOD1 transgenic male rats were randomly divided into three experimental groups: (i) transplanted with hNSCs (hNSC rats, n = 15); (ii) treated with HBSS (HBSS rats, n = 15) and (iii) untreated (CTRL rats, n = 22). An additional group of non-transgenic littermates (wild-type, WT, n = 9) were used as controls for symptomatic evaluation of the colony. Tacrolimus (FK506) and cyclosporine (cyclosporin A) are the principal immunosuppressive drugs that have been applied for solid organ transplantation55,56 and have been translated to stem cell treatments for PD57 and ALS22. In animal models, despite differences in potency, both drugs showed excellent survival rates for grafts across many comparative studies58,59. Our previous results44,45 showed that hNSCs can survive—without signs of rejection—in the rat brain up to 6 months under transient immunosuppression treatment, with cyclosporin A. On the bases of these results, we applied the same immunosuppressive treatment with administration of cyclosporine A (15 mg/kg/day subcutaneous; Sandimmne, Novartis) that was initiated on the day of transplantation and continued for 15 days after surgery (for all animal groups).

Mar 18, 2023

Tomorrow Biostasis: The Berlin Startup That Wants to Bring You Back from the Dead

Posted by in categories: biotech/medical, cryonics, life extension, neuroscience

What if death was not the end? What if, instead of saying our final goodbyes to loved ones, we could freeze their bodies and bring them back to life once medical technology has advanced enough to cure their fatal illnesses? This is the mission of Tomorrow Biostasis, a Berlin-based startup that specializes in cryopreservation.

Cryopreservation, also known as biostasis or cryonics, is the process of preserving a human body (or brain) in a state of suspended animation, with the hope that it can be revived in the future when medical technology has advanced enough to treat the original cause of death. This may seem like science fiction, but it is a legitimate scientific procedure, and Tomorrow Biostasis is one of the few companies in the world that offers this service.

Dr Emil Kendziorra, co-founder and CEO of Tomorrow Biostasis explained that the goal of cryopreservation is to extend life by preserving the body until a cure can be found for the original illness. He emphasized that cryopreservation is not a form of immortality, but rather a way to give people a second chance at life.

Jan 17, 2023

Inside the US facility that has cryofrozen 199 ‘patients’ and 100 pets

Posted by in categories: biotech/medical, cryonics, life extension

This American cryonics facility has preserved “patients” in liquid nitrogen-filled tanks until a future date when technology allows them to be thawed.

Page 1 of 2712345678Last